Essiac, in supplying the body with a secretion resistant to the onslaught of malignant cells, causes the growth to regress within itself. Being localised, the growth could be removed by surgery (without cutting into a large area of healthy cells surrounding the growth), and without the danger of a recurrence as in the present method of operating.

In the case of cancer of the breast, the primary growth will usually invade the mammary gland of the opposite breast or the axilla or both. If Essiac is administered either orally or by hypodermic injection into the forearm, the secondary growth will regress into the primary mass, enlarging it for a time, but when it is all localised, it will loosen and soften and can then be removed without the danger of recurrence. No matter where the malignancy may be in the human body, surgery would be much more successful after six to eight treatments with Essiac. If there is any suspicion that any malignant cells are left after the operation, then Essiac should be given once a week for at least three months, supplying the body with the resistance to a recurrence that is needed.

In the case of cancer of the lung, after localising with Essiac, it would be advisable to remove the lung along with the growth. The death rate from cancer surgery could be reduced to a minimum.

Many cancer cases would not require surgery if Essiac were given in time. This treatment goes right to the seat of the trouble and if given to a patient who is ailing (and there is any suspicion of cancer), it will cause the growth to localise and is easily found by fluoroscope or an x-ray. If there is no growth, the patients general condition will still improve. The rapid growing malignant cells are quicker to respond and much easier to cure than the slow growing type which is a harder and more compact mass of cells.